dr. erika p. hamilton on the shifting treatment paradigm in her2-positive breast cancer
Published 8 years ago • 249 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
0:57
dr. erika p. hamilton on ont-380 in her2-positive breast cancer patients with brain metastases
-
14:04
her2 positive breast cancer algorithm - oncbrothers (rohit & rahul gosain) w/ dr. erika hamilton
-
22:08
breast cancer asco 2024 practice changing highlights - discussion with dr. erika hamilton
-
30:57
treatment updated for her2 positive breast cancer: changing paradigms
-
1:43
dr hamilton on implications of destiny-breast06 on the her2-low breast cancer paradigm
-
1:16
dr. hamilton on the complex treatment algorithm for her2 breast cancer
-
20:11
her2-positive breast cancer—reduce your risk of recurrence | access health
-
8:47
what's new in breast cancer treatment in 2023 | top breast cancer docs discuss emerging research
-
18:38
how to treat triple negative breast cancer | dr. ruth o'regan chair & dr. anna weiss
-
1:57
dr. hamilton on phase 1 trial for her2 positive breast cancer - sarah cannon
-
35:50
evolving strategies for metastatic breast cancer: a deep dive into recent progress
-
1:01
dr. hamilton discusses challenges with approved treatments for her2-positive breast cancer
-
5:45
her2-positive breast cancer: a paradigm shift in diagnosis and therapy
-
1:40
erika hamilton, md, on promising treatment options in the management of her2 advanced breast cancer
-
1:53
dr. hamilton on adjuvant therapy for her2 breast cancer
-
0:51
dr. hamilton on extended adjuvant therapy for her2 breast cancer
-
0:57
dr. erika p. hamilton on ont-380 for her2 breast cancer
-
1:01
dr. hamilton on research needed in her2-positive breast cancer
-
14:52
her2 sabcs 2022 highlights - oncbrothers (rohit and rahul gosain) with dr. erika hamilton
-
3:48
dr. erika hamilton shares an important breast cancer research update - newsy
-
1:12
opportunities in er /her2- breast cancer care - erika p. hamilton, md
-
54:02
navigating shifts in the treatment landscape for metastatic her2-positive breast cancer